Candied Amla (Indian Gooseberry)

About

What it is and where it shows up.

Candied amla is sugar-preserved Indian gooseberry (Phyllanthus emblica L. / Emblica officinalis Gaertn.), a traditional South Asian confection produced by soaking whole or sliced amla fruits in concentrated sugar syrup. It retains bioactive compounds including vitamin C (193–720 mg/100 g in the fresh fruit), polyphenols, tannins, and dietary fibre while providing an extended shelf-life form of the fruit.

Safety summary

The regulatory and scientific consensus.

Amla at typical food and supplemental doses is well-tolerated; a randomised crossover clinical trial (500 mg/day for 18 weeks) reported no hepatotoxicity, adverse events, or meaningful changes in safety parameters. The candied form introduces a high added-sugar load that warrants caution for people managing blood glucose. Some preclinical literature notes a theoretical hepatotoxicity concern with long-term high-dose extract use, though this has not been demonstrated at normal dietary intake levels.

Regulatory landscape

What food-safety regulators have decided.

Jurisdiction	Status	Note
FSSAI (Food Safety and Standards Authority of India) (India)	Approved	Candied fruits and peels are explicitly recognised under FSS (Packaging and Labelling) Regulations, 2011, with specific packaging requirements. Amla is listed as a permitted food/fruit ingredient in FSSAI Appendix A (food category system) and is named in FSSAI Nutraceutical Regulations FAQ as a conventional fruit not requiring health supplement classification when minimally processed. No specific maximum daily intake limit is set for candied amla as a whole food product.source
FDA (Food and Drug Administration) (United States)	Approved	Indian gooseberry (amla) is consumed as a conventional food in the United States with no specific FDA ban or restriction. Whole-fruit and candied-fruit preparations are treated as conventional foods; no ADI has been established.source

Who should approach with care

Whose guidance would steer them away.

Diabetes — The candying process introduces a high added-sugar load; despite amla's own antidiabetic bioactive compounds documented in clinical trials, the overall high sugar content of the candied product may elevate postprandial blood glucose in diabetic individuals.

Liver Disease — Preclinical and review literature has flagged a theoretical hepatotoxicity concern with long-term high-dose amla extract consumption; individuals with pre-existing liver disease should consult a physician before regular high-quantity intake of amla-based products.

Children — The high added-sugar content inherent in the candying process is inconsistent with dietary guidance limiting added sugars for young children, making frequent consumption inadvisable for this age group.

Ibs — Amla is rich in tannins and dietary fibre; at high intake, these components may exacerbate gastrointestinal symptoms such as bloating or altered stool consistency in individuals with irritable bowel syndrome.

Research citations

The sources behind this verdict.

1PubMed. Functional and Nutraceutical Significance of Amla (Phyllanthus emblica L.): A Review, 2022. pmc.ncbi.nlm.nih.gov
2PubMed. Insight about the biochemical composition, postharvest processing, therapeutic potential of Indian gooseberry (amla), and its utilization in development of functional foods — A comprehensive review, 2022. pubmed.ncbi.nlm.nih.gov
3FSSAI. Food Safety and Standards (Packaging and Labelling) Regulations, 2011 — Compendium (updated 2022), 2022. fssai.gov.in
4PubMed. Clinical evaluation of Emblica Officinalis Gatertn (Amla) in healthy human subjects: Health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study, 2019. pmc.ncbi.nlm.nih.gov
5PubMed. Anticancer Properties of Phyllanthus emblica (Indian Gooseberry), 2015. pmc.ncbi.nlm.nih.gov

Independently researched5 citations